Insmed Inc (INSM)vsPulmatrix Inc (PULM)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PULM
Pulmatrix Inc
$2.12
-1.40%
HEALTHCARE · Cap: $8.25M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 20214000% more annual revenue ($606.42M vs $3,000). PULM leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PULM
Avoid19
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PULM
The strongest argument for PULM centers on Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PULM
The primary concerns for PULM are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PULM is a value play — different risk/reward profiles.
PULM carries more volatility with a beta of 1.73 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PULM generates stronger free cash flow (-706,000), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Pulmatrix Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Pulmatrix, Inc., a clinical-stage biopharmaceutical company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company is headquartered in Lexington, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?